al amyloidosis market insights, al amyloidosis market share, al amyloidosis market trends, al amyloidosis market demand, al amyloidosis market research, al amyloidosis market forecast
At what pace is the al amyloidosis market growing, and what is its estimated value?
The AL amyloidosis market size has grown rapidly in recent years. It will grow from $3.11 billion in 2024 to $3.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to growing awareness among healthcare providers about al amyloidosis, rising incidence of al amyloidosis, rising geriatric population, expansion of diagnostic centers, and improvement in cardiac imaging.
The AL amyloidosis market size is expected to see rapid growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to rise in incidences of mutations in blood cell DNA, growing healthcare infrastructure, growing incidence of multiple myeloma, introduction of combination therapies, and increasing use of high-dose chemotherapy. Major trends in the forecast period include advancements in diagnostic techniques, technological advancements in drug delivery, advancements in blood tests, development of targeted therapies, and adoption of artificial intelligence (AI) in diagnosis.
Get Your Free Sample of The Global AL Amyloidosis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20710&type=smp
What are the top drivers to the rising demand in the al amyloidosis market?
The rising incidence of plasma cell disorders is expected to propel the growth of the AL amyloidosis market going forward. Plasma cell disorders are conditions where abnormal plasma cells produce excessive or abnormal antibodies, potentially causing organ damage. The rising incidence of plasma cell disorders is attributed to factors such as an aging population, increased life expectancy, and advancements in diagnostic technologies. AL amyloidosis is a condition that arises from plasma cell disorders, specifically the overproduction of abnormal light chain proteins, which can lead to the accumulation of amyloid deposits in organs and tissues, further exacerbating the effects of plasma cell dyscrasias. For instance, in August 2024, according to the reports published by The American Cancer Society (ACS), a US-based nonprofit organization, in 2024, about 35,780 new cases of multiple myeloma are expected to be diagnosed (19,520 in men and 16,260 in women), and around 12,540 deaths are projected, with 7,020 in men and 5,520 in women. Therefore, the rising incidence of plasma cell disorders is driving the growth of the AL amyloidosis market.
How is the al amyloidosis market segmented?
The AL amyloidosis market covered in this report is segmented –
1) By Treatment: Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant, Targeted Therapy
2) By Drugs: Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs
3) By Route Of Administration: Intravenous, Oral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy
2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)
3) By Surgery: Organ Transplantation, Debulking Surgery
4) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
5) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report
Who are the top competitors in the al amyloidosis market?
Major companies operating in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, Attralus Inc.
What significant trends should we anticipate in the al amyloidosis market over the forecast period?
Major companies operating in the AL amyloidosis market are focusing on developing innovative therapies such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy to improve treatment efficacy and patient outcomes. Next-generation BCMA-directed CAR T-cell therapy refers to an advanced form of immunotherapy that involves engineering a patient’s T cells to target and attack BCMA on the surface of cancer cells, specifically in multiple myeloma. For instance, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for NXC-201 for the treatment of a life-threatening blood disorder, Amyloid Light Chain (AL) Amyloidosis. NXC-201 is a next-generation CAR-T cell therapy being tested in clinical trials for the treatment of amyloid light chain (AL) amyloidosis, showing promising results with a 100% hematologic response rate and organ improvements in patients who had failed previous treatments.
Which regional trends are influencing the al amyloidosis market, and which area dominates the industry?
North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The AL Amyloidosis Market Report 2025 Offer?
The al amyloidosis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
AL Amyloidosis is a rare and serious condition where abnormal proteins, called light chains, are produced by plasma cells in the bone marrow. These light chains misfold and form amyloid fibrils, which then deposit in various organs and tissues, impairing their function. Commonly affected organs include the heart, kidneys, liver, and nervous system. Symptoms vary depending on the organs involved but may include fatigue, swelling, shortness of breath, numbness, and organ dysfunction.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20710
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
